Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

2022年 12月 05日

Read More

Zai Lab to Present Interim Overall Survival Results for ZEJULA® (niraparib) from the Phase 3 NORA Study at the ESMO Virtual Plenary

2022年 12月 01日

Read More

Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates

2022年 11月 09日

Read More

Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting

2022年 11月 08日

Read More

Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer

2022年 11月 08日

Read More

Zai Lab Announces Participation in November Investor Conferences

2022年 10月 31日

Read More

Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022

2022年 10月 18日

Read More

Zai Lab Launches its first Trust Report

2022年 10月 14日

Read More